|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and pa- tient(PT)-reported outcomes (PROS) with selumetinib (AZD6244,ARRY-142866;SEL) + docetaxel (DOG) in KRAS-mutant advanced randomized,phase Ⅱ trial 显示文摘 | Janne PA Shaw AT Rodrigues PJ | 2012 | ESMO Abstract 1233PD2012，1233，： | 1 |
| 2 | Clinical activity of crizotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement 显示文摘 | Shaw AT Camidge DR Engelman J | 2012 | Ann Oncol2012，30，： | 1 |
| 3 | E,laluation of cerltinlb- treated patients with anaplastic lymphoma kinase rearranged ( ALK + ) non-small cell lung cancer (NSCLC) and brain metas- tases in the ascend-1 study 显示文摘 | SHAW AT MEHRA R TAN DSW | 2014 | Ann Oncol2014，25，4： | 1 |
| 4 | Crizotinib in ROSl-rearranged non-small- cell lung cancer显示文摘 | Shaw AT Solomon BJ | 2015 | N Engl J Med2015，372，7： | 1 |
| 5 | Selumetinib plus do-cetaxel for K-Ras-mutant advanced non-small-cell lung cancer : arandomized,multicentre, placebo-controlled,phase2 study 显示文摘 | Janne PA Shaw AT Pereira JR | 2013 | Lancet Oncol2013，14，1： | 1 |
| 6 | Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK显示文摘 | Shaw AT Yeap BY Mino-Kenudson M | 2009 | J Clin Oncol2009，27，26： | 1 |
| 7 | Novehargets in non-small cell lung cancer: ROS1 and RET fusions 显示文摘 | Gainor JF Shaw AT | 2013 | Oncologist2013，18，7： | 1 |
| 8 | Crizotinib versus chemotherapy in advanced ALK-positive lung cancer 显示文摘 | Shaw AT Kim DW Nagawa K et | 2013 | N Engl J Med2013，368，25： | 1 |
| 9 | Characterization of a secreted Chlamydia protease 显示文摘 | SHAW A C VANDAHL B B LARSEN M R et at | 2002 | Cell Microbiol2002，4，： | 1 |
| 10 | Endogenous oncogenic K-ras (G12D) stimulates proliferation and widespread neoplastic and developmental defects 显示文摘 | Tuveson DA Shaw AT Willis NA | 2004 | Cancer Cell2004，5，4： | 1 |
| 11 | Targeting anaplastic lymphoma kinase in lungcancer显示文摘 | Shaw AT Solomon B | 2011 | Clin Cancer Res2011，17，8： | 1 |
| 12 | ROS1 rearrangements define a u-nique molecular class of lung cancers显示文摘 | Bergethon K Shaw AT Ou SH | | 0，，： | 1 |
| 13 | Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer:A randomised,multicentre,placebo-controlled,phase 2 study显示文摘 | Janne PA Shaw AT Pereira JR | 2013 | Lancet Oncol2013，14，： | 1 |
| 14 | Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers显示文摘 | Katayama R Shaw AT Khan TM | 2012 | Sci Transl Med2012，4，12： | 1 |
| 15 | Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases显示文摘 | Costa DB Shaw AT Ou SH | 2015 | J Clin Oncol2015，33，17： | 1 |
| 16 | Clinical activity of the oral ALK i nhibitor,PF-02341066, in ALK-positive patients with non- small cell lung cancer (NSCLC) 显示文摘 | Bang Y Kwak EL Shaw AT | 2010 | J Clin Oncol2010，27，15： | 1 |
| 17 | Clinical activity of the ALK inhibitor LDK378 in advanced,ALK-positive NSCLC 显示文摘 | Shaw AT Mehra R Kim DW | 2013 | J Clin Oncol2013，，： | 1 |
| 18 | Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK显示文摘 | Shaw AT Yeap BY Mino-Kenudson M | 2009 | J Clin Onco2009，27，26： | 1 |
| 19 | Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement:a retrospective analysis显示文摘 | Shaw AT Yeap BY Solomon BJ | | 0，，： | 1 |
| 20 | Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK显示文摘 | Shaw AT Yeap BY Mino-Kenudson M | | 0，，26： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员